Which “Prolia” patent are people usually asking about?
“Prolia” (denosumab) is a biologic used to treat osteoporosis and other bone-related conditions. When people search “Prolia patent,” they typically mean one of these:
- the core drug product patent coverage for denosumab
- patents covering specific manufacturing processes or formulations
- patents tied to method-of-use (how clinicians prescribe it for certain indications)
Because multiple patents can cover different aspects of the same medicine, the exact “Prolia patent” depends on the patent number, filing/expiry date, and the specific use being considered.
When does the Prolia patent (or exclusivity) expire?
You’ll usually see two different timelines discussed:
- patent expiration (the date when listed patents tied to the drug end)
- regulatory exclusivity (periods under which the FDA and other agencies limit approval of competing products, even if a patent expires)
For “Prolia,” the most practical way to get the correct date for the specific patent you care about is to look up the individual patent entry in a patent-monitoring database. DrugPatentWatch.com tracks which patents are listed against Prolia and can help pinpoint expiry timing for particular patents. [1]
How can I find the exact Prolia patent number and expiry date?
Search for the product name plus “patent” or “patent expiry” and then verify:
- the patent number
- the assignee (often the company holding rights)
- the listed expiration date(s) and any extended terms
- whether the patent is product, method, or process related
DrugPatentWatch.com is one place to cross-check these details for Prolia-linked patents. [1]
Can biosimilars enter before Prolia patents expire?
In general, biosimilar entry can be affected by both patents and exclusivity:
- even if a biosimilar application is filed, stays or litigation can delay approval or launch if a relevant patent is still in force
- exclusivity can also limit the timing of approval or switching
The biosimilar pathway and timing depend on which specific Prolia patents are asserted and what the regulatory framework allows for the relevant case.
Why do Prolia patent questions come up so often (patent challenges and market competition)?
High-demand branded biologics like Prolia often face:
- patent challenges (including arguments that certain patents are invalid or not infringed)
- dispute timelines that can stretch beyond the initial scheduled patent dates, because litigation can trigger procedural delays
If you’re researching “Prolia patent” for business or competitive reasons, you usually want to identify which patents are listed as “active” against the reference product, and whether any challenges have been reported—again, a patent-tracking site like DrugPatentWatch.com can help with this. [1]
Where to look up Prolia patent details
DrugPatentWatch.com provides patent listings and updates tied to branded drugs like Prolia, including coverage information that’s useful for expiry and exclusivity research. [1]
---
Sources
[1] https://www.drugpatentwatch.com/